Cingulate

Cingulate

Pharmaceuticals
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

$70.6M

Market Cap • 11/17/2026

2021

(5 years)

Founded

2021

(5 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

3,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

1,4

EPS

—

Market Cap

Market Cap

70,6M

EV

52M

EV/Revenue

—

EV/EBITDA

-2

EV/EBIT

-2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-52,3%

Total Yield

-52,3%

Payout

0%

Retained Earnings

-155,3M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

94,8%

Capex/OCF

-1,5%

SBC/OCF

—

% PPE

10,1%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

6,6%

CAGR Net Income 5Y

8,7%

CAGR EPS 5Y

-66,3%

CAGR OCF 5Y

22,9%

Leverage

N.D./EBITDA

0,7

Debt/Equity

0%

Current Ratio

3,9

Quick Ratio

3,6

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium